semaj83/ctmatch_classification huggingface dataset:
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-35.0,  Vestibulodynia non pregnant women between 18-35 naïve to HCs or other hormonal medications Patients able to provide Informed Consent and complete questionnaires Patient intends to use HCs for at least one year On exam before initiation of HCs, patient does not have primary PVD, pelvic floor hypertonicity, vaginismus or congenital abnormalities Patient will be available for follow up appointments Patient is willing to undergo gynecologic examination, if dyspareunia develops  Patients with endocrine disturbances (including PCOS), liver diseases and eating disorders Patients who suffer from Hypertension, Migraine with aura or clotting disturbances Patients that experience pain with intercourse or tampon insertion Patients that have other contraindications for HCs use
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-0.154,  Infantile Colic otherwise healthy infants crying/fussing more than three hours/day more than three days in the same week has tried cow´s milk protein free diet for at least five days  born before week 36 has tried acupuncture treatment dont gain weight properly taking other medicine than dimethicone or lactobacillus reuteri parents who don´t understand Swedish
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 16.0-999.0,  Infection in Solid Organ Transplant Recipients Solid organ transplant recipient. 2. 16 years or older. 3. More than 30 days after transplantation. 4. Negative pregnancy test for women of childbearing potential 5. The patient must give informed consent  No written informed consent. 2. Acute rejection within 15 days prior to vaccination. 3. Pregnancy. 4. Hypersensitivity to the active substance, any of the excipients and waste, for example: eggs, egg albumin, chicken proteins. 5. History of a previous serious reaction to immunization (eg Guillain-Barré syndrome)
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hepatocellular Cancer Histologically confirmed advanced HCC Barcelona Clinic Liver Cancer stage C or stage B if you cannot tolerate or failed TACE No cirrhosis or Child-Pugh A cirrhosis Measurable lesions All acute toxic effects of any prior treatment have resolved to NCI-CTCAE v4.0 grade 1 or less Able to swallow and retain oral medication  Prior systemic regimens for HCC Uncontrolled hypertension CLIP score > 3 ECOG PS > 1 Clinically apparent central nervous system metastases or carcinomatous meningitis Pregnant or breastfeeding Active or clinically significant cardiac disease Evidence or history of bleeding diathesis or coagulopathy Any pulmonary hemorrhage/bleeding event of NCI-CTCAE v4.0 Grade 2 or higher within 4 weeks of enrollment Presence of a non-healing wound, non-healing ulcer, or bone fracture
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-64.0,  Influenza Main 1. Provide written informed consent 2. Males or females aged 18-64 years, inclusive 3. Symptomatic presumptive influenza A or B infection defined as the presence of: 1. a fever of ≥38.0ºC (≥100.4 ºF) at the screening visit OR a history of fever within the 24 hours prior to the screening visit and has administered antipyretic(s) in the 6 hours prior to the screening visit AND 2. ≥1 moderate systemic symptom (headache, feeling feverish, body aches and pains, and fatigue) AND 3. ≥1 moderate respiratory symptom (cough, sore throat and nasal congestion) 4. Onset of illness no more than 40 hours prior to randomization. Onset of illness is defined as the time, the first of any one of the following, occurred: 1. time when the subjects' temperature was measured as elevated (≥38.0°C (≥100.4ºF) OR 2. time when the subject first experienced at least one respiratory symptom (cough, sore throat and nasal congestion) OR 3. time when the subject first experienced at least one systemic symptom (headache, feeling feverish, body aches and pains, and fatigue) Main  Use of antiviral treatment for influenza (e.g. zanamivir, oseltamivir, rimantadine, or amantadine) within 14 days prior to screening 2. Received live attenuated or trivalent inactivated influenza virus vaccine in the previous 3 weeks. 3. History or presence of clinically significant pulmonary disease (e.g., chronic obstructive pulmonary disease, cystic fibrosis, or bronchiectasis) or asthma 4. History of congestive heart failure with symptoms consistent with New York Heart Association Class III or IV functional status (See Appendix A: ) within the past 12 months 5. Presence of an immune compromised status due to chronic illness, organ transplantation or use of daily systemic immunosuppressants 6. Presence of clinically significant signs of acute respiratory distress during screening 7. Current use of inhaled medications (nasal or oral) or anticipated use of inhaled medications (nasal or oral) at any time during the study. 8. Current or a history of acute or chronic renal impairment requiring hemodialysis and/or a known or calculated creatinine clearance (CLCR) of <60 mL/min 9. History or presence of any clinical condition or evidence of organ dysfunction on examination which, in the opinion of the investigator, may affect either the subject's ability to participate in the study or the study results
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 22.0-35.0,  Nutritional Anemia in Mothers. Nutritional Anemia in Infants. Hb level in the range of 7.0-11 g/dL 2. Age: 22-35 years 3. Mothers at the beginning of second trimester (i.e. at 11-14 weeks of gestation) 4. Willing to stay in Dhaka during pregnancy and willing to get admitted in the clinic for delivery 5. Self-reported Last Menstrual Period (LMP) and urine pregnancy test will be used to determine the gestational age  Women with severe anemia; hemoglobin concentration <7.0 g/dL 2. History or presence of systemic disease 3. H/O of previous complicated pregnancies or of pre-term delivery, abortion 4. Receipt of influenza vaccine
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Pruritus Patients w/ histologically confirmed mycosis fungoides stage IB to IVA eligible to receive oral vorinostat Patients w/ stage IB to IV reporting pruritus Patients age 18-85 years, of any race, sex, and ethnicity Life expectancy > 24 weeks Patient must have performance status of ≤2 on the ECOG Performance Scale Patients w/ a min. of 3 weeks since their last systemic treatment Women who are not pregnant, lactating, or of childbearing potential Female patients w/ reproductive potential must use an adequate contraceptive method during treatment and for three months after completing treatment Male patient w/ reproductive potential, agrees to use an adequate method of contraception for the duration of the study and for 30 days beyond the duration of study Patients, or legal representative must to be willing to adhere to the protocol, and sign an Informed Patient Consent Form prior to entry into the study  Patients w/ a recent cardiac history, such as a myocardial infarct within the last year, uncontrolled angina, severe uncontrolled ventricular arrhythmias, clinically significant pericardial disease, or electrocardiographic evidence of acute ischemic or active conduction system abnormalities Patients w/ a history of liver damage (2.5 x normal ALT, AST), leukopenia, or thrombocytopenia Women who are pregnant or nursing a child Patients w/ severe emotional, behavioral or psychiatric problems that, in the opinion of the investigator, would result in poor compliance with the treatment regimen Patients who have received and histone deacetylase inhibitor within the last 6 months Patients receiving valproic acid will be excluded unless there has been a wash-out period of 30 or more days Patients who will have received systemic therapy, radiation therapy or phototherapy within 3 weeks prior to initial dosing with study drugs or who has not recovered from adverse events due to agents administered more than 3 weeks earlier QTc prolongation greater than 500ms Patient w/ a "currently active" second malignancy, other than non-melanoma skin cancer and carcinoma in situ of the cervix, should not be enrolled Patients are not considered to have a "currently active" malignancy if they have completed therapy for a prior malignancy, are disease free from prior malignancies for >5 years or are considered by their physician to be at less than 30% risk of relapse
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 45.0-999.0,  This Study Has Been Designed to Compile Information on the Efficacy of the Partial Breast Intracavitary Brachytherapy in the Post Market Setting. Be 45 years of age or older Be a Tis, T1, N0 M0 American Joint Committee Classification Have negative surgical margins (NSABP definition) after final surgery Should have adequate skin spacing between balloon surface and surface of the skin (>=7mm) DCIS  Be pregnant or breast-feeding.(If appropriate, patient must use birth control during the study) Have collagen-vascular disease Have extensive intraductal component (Harvard Definition,>25% DCIS) Have infiltrating lobular histology
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-100.0,  Influenza Age 18-30, 60-79, or 80-100 years, inclusive at time of initial enrollment General good health and ambulatory at time of enrollment No acute illness at time of vaccination Willing and able to sign Informed Consent Available for follow-up for the planned duration of the study Acceptable medical history by screening evaluation and brief clinical assessment All female subjects of childbearing potential must use an acceptable method of contraception and not become pregnant for the duration of the clinical phase of the study (approximately 1 month to completion of Visit 3). (Acceptable contraception may implants, injectables, combined oral contraceptives, effective intrauterine devices (IUDs), sexual abstinence, or a vasectomized partner)  Prior off-study vaccination with trivalent or quadrivalent (depending no year) influenza vaccine (TIV or IIV4) or live attenuated influenza vaccine (LAIV) in the current flu season Allergy to egg or egg products Allergy to vaccine components, including thimerosal Active systemic or serious concurrent illness, including febrile illness on the day of vaccination History of immunodeficiency Any chronic disorder which, in the opinion of the investigator, might jeopardize volunteer safety or compliance with the protocol Blood pressure >150 systolic or > 95 diastolic at Visit 1 Chronic Hepatitis B or C Recent or current use of systemic immunosuppressive medication, including glucocorticoids (corticosteroid nasal sprays and inhaled steroids are permissible). Use of oral steroids (<20mg prednisone-equivalent/day) may be acceptable after review by the investigator Autoimmune disease (including rheumatoid arthritis treated with immunosuppressive medication such as Plaquenil, methotrexate, prednisone, Enbrel) which, in the opinion of the investigator, might jeopardize volunteer safety or compliance with the protocol
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.126-0.208,  Neisseria Meningitidis Bacterial Infections Virus Diseases Healthy infant 46 to 74 days (both inclusive) Documented receipt of only one dose of monovalent hepatitis B vaccine within the 3 days after birth Parent(s)/legal representative able to comply with the study procedures  Participation in any study with an investigational compound or device since birth History of congenital or acquired immunodeficiency Chronic illness that could interfere with study conduct or completion Hypersensitivity to any of the study vaccines components or history of a life-threatening reaction to a vaccine containing the same substances as the study vaccines Contraindication to Pediacel®, NeisVac-C®, Prevenar 13®, and RotaTeq® History or maternal history of HBsAg seropositivity Coagulation disorder that contraindicate intramuscular injection History of vaccination with a Haemophilus influenzae type b conjugate, diphtheria, tetanus, pertussis (acelullar or whole-cell), poliovirus, meningococcal serogroup C conjugate, pneumococcal conjugate containing vaccine(s) History of hepatitis B, Haemophilus influenzae type b, diphtheria, tetanus, pertussis, poliomyelitis, or serogroup C meningococcal infection Receipt of immune globulin, blood or blood-derived products since birth
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer HER2-positive Stage I histologically confirmed invasive carcinoma of the breast ER/PR determination is required HER2 positive, confirmed by central testing: IHC 3+, FISH HER2/CEP17 <2.0 with an average HER2 copy number >/=6.0, or FISH HER2/CEP17 >/= 2.0 Bilateral breast cancers that individually meet are allowed Subjects with multifocal or multicentric disease are eligible as long as each tumor individually meets Subjects with a history of ipsilateral DCIS are eligible if they were treated with wide-excision alone, without radiation therapy; Patients with a history of contralateral DCIS are not eligible Should have tumor tissue available and a tissue block of sufficient size to make 15 slides, which must be sent to a DFCI site for testing Less than or equal to 90 days since most recent breast surgery for this breast cancer All tumor should be removed by either a modified radical mastectomy or a segmental mastectomy (lumpectomy) with either a sentinel node biopsy or axillary dissection All margins should be clear of invasive cancer or DCIS  Pregnant or breastfeeding Use of potent CYP3A4 inhibitors during the study treatment period Excessive alcohol intake (more than 3 alcoholic beverages per day) Locally advanced tumors at diagnosis History of previous invasive breast cancer History of prior chemotherapy in the past 5 years History of prior trastuzumab or prior paclitaxel therapy Active, unresolved infection Active liver disease History of a different malignancy except for the following: disease free for at least 5 years and at low risk for recurrence; cervical cancer in situ, basal or squamous cell carcinoma of the skin
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Psoriasis Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the trial. 2. Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. 3. Be at least 18 years of age at time of informed consent. 4. Have had a diagnosis of plaque-type psoriasis (psoriasis vulgaris). 5. Subject is about to start a new kind of therapeutic treatment, either topical, phototherapy, systemic, or biologic agent  Subject is not over 18 years of age. 2. Subject cannot understand or follow directions. 3. Subject is a female of child-bearing potential and unwilling to use a form of highly effective birth control. 4. Subject is pregnant or planning to get pregnant
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 12.0-60.0,  Influenza, Human Immunisation Reaction aged 12-60 years old male or non-pregnant female volunteers received 2010 seasonal influenza vaccine clinically healthy as determined by: medical history inquiring and physical examination provide written informed consents before joining the trial  without history of 2010 seasonal influenza vaccine administration allergic to any ingredient of vaccine autoimmune disease or immunodeficiency severe adverse reaction after vaccination, such as allergies, hives, breathing difficulties, angioedema or abdominal pain severe acute and chronic diseases axillary temperature over 37.0℃ at the time of vaccination
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-64.0,  H7N9 Influenza Healthy adult subject ages 18-64 years. 2. Individuals willing to provide written informed consent 3. Individuals in good health. 4. Individuals who can comply with study procedures and follow-up  Individuals with history of cognitive or behavioral impairment or psychiatric disease, 2. Individuals unable to understand and follow study procedures, 3. History of significant illness, 4. History of chronic medical condition or progressive disease, 5. Allergy to any vaccine component or adverse event related to a vaccine component, 6. Impairment/alteration of the immune system, 7. Presence of progressive or severe neurological disorder, 8. Pregnant or breast-feeding, 9. Female of Child-bearing potential unwilling to use acceptable method of birth control, 10. Presence of medically significant cancer, 11. Receipt of investigational product within 30 day prior to entry into the study, 12. History of previous or suspected illness from avian flu caused by H7N9 virus, 13. History of H7 vaccination, 14. Body temperature of greater than or equal to 38.0°C (100.4◦F) and/or acute illness within 3 days of intended study vaccination, 15. Receipt of any flu vaccination 2 weeks before study entry or 4 weeks after study vaccination, 16. Receipt of any vaccination 2 weeks before study entry or 4 weeks after study vaccination, 17. History of drug or alcohol abuse within the past 2 years, 18. Body Mass Index (BMI) greater than or equal to 35kg/m2, 19. Individuals conducting the study or their immediate family members
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 12.0-50.0,  Urticaria Clinical diagnosis of persistent allergic urticaria Age over 12 years and at least one year with the disease Informed consent filled Be resident of the metropolitan area of Medellin  • Use of immunosuppressive drugs